<p>Viridian Therapeutics, Inc.（納斯達克代碼：VRDN - 獲取免費報告）在週四創下了 52 周的新高，此前公司發佈了超出預期的財報。該股最高交易價為 28.59 美元，最後交易價為 28.2170 美元，成交量為 1730401 股。該股票此前收盤價為 24.42 美元。</p>
<p>該公司報告本季度每股收益為（0.34 美元），超出市場共識預期的（0.82 美元）0.48 美元。Viridian Therapeutics 的淨利潤率為負 112,806.88%，股本回報率為負 78.95%。該公司本季度的收入為 70,000 美元，而分析師預期為 1621,000 美元。與去年同期相比，該公司的季度收入增長了 81,993.0%。</p>
<p>獲取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
<h2>分析師設定新目標價</h2>
<p>多位分析師最近對該公司進行了評論。高盛集團在週四的研究報告中重申了對 Viridian Therapeutics 股票的 “買入” 評級。Oppenheimer 在 10 月 21 日的研究報告中將 Viridian Therapeutics 的目標價從 32.00 美元上調至 36.00 美元，並給予該股票 “跑贏大盤” 的評級。Needham &amp; Company LLC 在 8 月 6 日的研究報告中將 Viridian Therapeutics 的目標價從 36.00 美元下調至 34.00 美元，並對該股票設定了 “買入” 評級。BTIG Research 在週二的研究報告中重新發布了 “買入” 評級，並對 Viridian Therapeutics 的股票設定了 61.00 美元的目標價。最後，Jefferies Financial Group 在 8 月 25 日的研究報告中開始覆蓋 Viridian Therapeutics，給予 “買入” 評級和 44.00 美元的目標價。九位研究分析師對該股票給予了 “買入” 評級，一位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 38.22 美元。</p>
<p><strong>查看我們關於 Viridian Therapeutics 的最新研究報告</strong></p>
<h2>Viridian Therapeutics 的內部交易</h2>
<p>在其他消息中，董事 Fairmount Funds Management Llc 在 10 月 23 日的交易中購買了 454,545 股該股票。該股票的平均購買成本為每股 22.00 美元，總交易額為 9,999,990.00 美元。收購後，該董事持有公司 3,914,458 股股票，價值 86,118,076 美元。此次交易使其持股增加了 13.14%。該收購在向 SEC 的備案中披露，相關信息可通過此鏈接訪問。1.58% 的股票由公司內部人士持有。</p>
<h2>機構投資者對 Viridian Therapeutics 的看法</h2>
<p>機構投資者最近對該公司的持倉進行了調整。Bessemer Group Inc.在第三季度將其在 Viridian Therapeutics 的持倉增加了 947.7%。Bessemer Group Inc.目前持有 2,085 股該公司的股票，價值 45,000 美元，此前在該期間又購買了 1,886 股。Principal Financial Group Inc.在第三季度將其在 Viridian Therapeutics 的持倉增加了 4.7%。Principal Financial Group Inc.目前持有 213,329 股該公司的股票，價值 4,604,000 美元，此前又購買了 9,493 股。AlphaQuest LLC 在第三季度將其在 Viridian Therapeutics 的持倉增加了 1,695.0%。AlphaQuest LLC 目前持有 17,645 股該公司的股票，價值 381,000 美元，此前在上個季度又收購了 16,662 股。Knights of Columbus Asset Advisors LLC 在第三季度將其在 Viridian Therapeutics 的持倉增加了 2.4%。Knights of Columbus Asset Advisors LLC 目前持有 59,410 股該公司的股票，價值 1,282,000 美元，此前在上個季度又收購了 1,386 股。最後，Y Intercept Hong Kong Ltd 在第三季度將其在 Viridian Therapeutics 的持倉增加了 430.3%。Y Intercept Hong Kong Ltd 目前持有 64,594 股該公司的股票，價值 1,394,000 美元，此前在上個季度又收購了 52,414 股。</p>
<h2>Viridian Therapeutics 股票表現</h2>
<p>該公司的 50 日移動平均線為 20.94 美元，200 日移動平均線為 17.34 美元。該股票的市值為 22.5 億美元，市盈率為-7.37，貝塔值為 0.49。該公司的債務與股本比率為 0.04，速動比率為 11.01，流動比率為 11.01。</p>
<h2>關於 Viridian Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Viridian Therapeutics, Inc.是一家生物技術公司，致力於發現和開發嚴重和罕見疾病的治療方案。該公司的產品管線包括 VRDN-001，一種針對類胰島素生長因子-1 受體的單克隆抗體，目前正在進行治療甲狀腺眼病（TED）的三期臨牀試驗；以及 VRDN-003，一種下一代 IGF-1R 人源化單克隆抗體，針對 IGF-1R 並結合半衰期延長技術用於治療 TED。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Viridian Therapeutics</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>Dutch Bros 連續第 11 個季度超預期盈利</li>
<li>投資汽車股票</li>
<li>從分紅到增長：為什麼這三隻股票在 2025 年脱穎而出</li>
<li>投資者如何找到最佳的便宜分紅股票</li>
<li>AMD 的價格回調意味着機會：大幅收益即將到來</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Viridian Therapeutics 嗎？</h2>
<p>在考慮 Viridian Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Viridian Therapeutics 並不在名單上。</p>
<p>雖然 Viridian Therapeutics 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

VRDN

<p>Viridian Therapeutics（納斯達克代碼：VRDN）在報告出乎意料的盈利後，達到了新的 12 個月高點 28.59 美元，每股收益（EPS）為（0.34 美元），而市場共識預期為（0.82 美元）。該股票收盤價為 28.2170 美元，較 24.42 美元上漲。分析師們設定了新的價格目標，Oppenheimer 將其目標上調至 36.00 美元，而 BTIG 則維持 61.00 美元的目標。機構投資者也顯著增加了他們的持股比例。該公司專注於開發嚴重疾病的治療方案，目前有針對甲狀腺眼病的產品在臨牀試驗中</p>

<p>Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) hit a new 52-week high on Thursday following a better than expected earnings announcement. The company traded as high as $28.59 and last traded at $28.2170, with a volume of 1730401 shares changing hands. The stock had previously closed at $24.42.</p>
<div class="lb-trans"><p>Viridian Therapeutics, Inc.（納斯達克代碼：VRDN - 獲取免費報告）在週四創下了 52 周的新高，此前公司發佈了超出預期的財報。該股最高交易價為 28.59 美元，最後交易價為 28.2170 美元，成交量為 1730401 股。該股票此前收盤價為 24.42 美元。</p>
</div><p>The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $16.21 million. The business's revenue for the quarter was up 81993.0% compared to the same quarter last year.</p>
<div class="lb-trans"><p>該公司報告本季度每股收益為（0.34 美元），超出市場共識預期的（0.82 美元）0.48 美元。Viridian Therapeutics 的淨利潤率為負 112,806.88%，股本回報率為負 78.95%。該公司本季度的收入為 70,000 美元，而分析師預期為 1621,000 美元。與去年同期相比，該公司的季度收入增長了 81,993.0%。</p>
</div><p>Get <strong>Viridian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of analysts recently commented on the company. The Goldman Sachs Group reaffirmed a &#34;buy&#34; rating on shares of Viridian Therapeutics in a research note on Thursday. Oppenheimer raised their price target on Viridian Therapeutics from $32.00 to $36.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, October 21st. Needham &amp; Company LLC decreased their price target on Viridian Therapeutics from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, August 6th. BTIG Research reissued a &#34;buy&#34; rating and issued a $61.00 price target on shares of Viridian Therapeutics in a research note on Tuesday. Finally, Jefferies Financial Group started coverage on Viridian Therapeutics in a research note on Monday, August 25th. They issued a &#34;buy&#34; rating and a $44.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.22.</p>
<div class="lb-trans"><p>多位分析師最近對該公司進行了評論。高盛集團在週四的研究報告中重申了對 Viridian Therapeutics 股票的 “買入” 評級。Oppenheimer 在 10 月 21 日的研究報告中將 Viridian Therapeutics 的目標價從 32.00 美元上調至 36.00 美元，並給予該股票 “跑贏大盤” 的評級。Needham &amp; Company LLC 在 8 月 6 日的研究報告中將 Viridian Therapeutics 的目標價從 36.00 美元下調至 34.00 美元，並對該股票設定了 “買入” 評級。BTIG Research 在週二的研究報告中重新發布了 “買入” 評級，並對 Viridian Therapeutics 的股票設定了 61.00 美元的目標價。最後，Jefferies Financial Group 在 8 月 25 日的研究報告中開始覆蓋 Viridian Therapeutics，給予 “買入” 評級和 44.00 美元的目標價。九位研究分析師對該股票給予了 “買入” 評級，一位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 38.22 美元。</p>
</div><p><strong>View Our Latest Research Report on Viridian Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Viridian Therapeutics 的最新研究報告</strong></p>
</div><h2>Insider Transactions at Viridian Therapeutics</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 的內部交易</h2>
</div><p>In other news, Director Fairmount Funds Management Llc purchased 454,545 shares of the stock in a transaction dated Thursday, October 23rd. The stock was acquired at an average cost of $22.00 per share, for a total transaction of $9,999,990.00. Following the acquisition, the director owned 3,914,458 shares of the company's stock, valued at $86,118,076. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 1.58% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Fairmount Funds Management Llc 在 10 月 23 日的交易中購買了 454,545 股該股票。該股票的平均購買成本為每股 22.00 美元，總交易額為 9,999,990.00 美元。收購後，該董事持有公司 3,914,458 股股票，價值 86,118,076 美元。此次交易使其持股增加了 13.14%。該收購在向 SEC 的備案中披露，相關信息可通過此鏈接訪問。1.58% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Viridian Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Viridian Therapeutics 的看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. Bessemer Group Inc. boosted its position in shares of Viridian Therapeutics by 947.7% in the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company's stock valued at $45,000 after purchasing an additional 1,886 shares during the period. Principal Financial Group Inc. boosted its position in shares of Viridian Therapeutics by 4.7% in the 3rd quarter. Principal Financial Group Inc. now owns 213,329 shares of the company's stock valued at $4,604,000 after purchasing an additional 9,493 shares during the period. AlphaQuest LLC lifted its stake in Viridian Therapeutics by 1,695.0% in the 3rd quarter. AlphaQuest LLC now owns 17,645 shares of the company's stock worth $381,000 after acquiring an additional 16,662 shares in the last quarter. Knights of Columbus Asset Advisors LLC lifted its stake in Viridian Therapeutics by 2.4% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company's stock worth $1,282,000 after acquiring an additional 1,386 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its stake in Viridian Therapeutics by 430.3% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company's stock worth $1,394,000 after acquiring an additional 52,414 shares in the last quarter.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。Bessemer Group Inc.在第三季度將其在 Viridian Therapeutics 的持倉增加了 947.7%。Bessemer Group Inc.目前持有 2,085 股該公司的股票，價值 45,000 美元，此前在該期間又購買了 1,886 股。Principal Financial Group Inc.在第三季度將其在 Viridian Therapeutics 的持倉增加了 4.7%。Principal Financial Group Inc.目前持有 213,329 股該公司的股票，價值 4,604,000 美元，此前又購買了 9,493 股。AlphaQuest LLC 在第三季度將其在 Viridian Therapeutics 的持倉增加了 1,695.0%。AlphaQuest LLC 目前持有 17,645 股該公司的股票，價值 381,000 美元，此前在上個季度又收購了 16,662 股。Knights of Columbus Asset Advisors LLC 在第三季度將其在 Viridian Therapeutics 的持倉增加了 2.4%。Knights of Columbus Asset Advisors LLC 目前持有 59,410 股該公司的股票，價值 1,282,000 美元，此前在上個季度又收購了 1,386 股。最後，Y Intercept Hong Kong Ltd 在第三季度將其在 Viridian Therapeutics 的持倉增加了 430.3%。Y Intercept Hong Kong Ltd 目前持有 64,594 股該公司的股票，價值 1,394,000 美元，此前在上個季度又收購了 52,414 股。</p>
</div><h2>Viridian Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 股票表現</h2>
</div><p>The firm has a 50 day moving average of $20.94 and a 200-day moving average of $17.34. The stock has a market capitalization of $2.25 billion, a PE ratio of -7.37 and a beta of 0.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.01 and a current ratio of 11.01.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 20.94 美元，200 日移動平均線為 17.34 美元。該股票的市值為 22.5 億美元，市盈率為-7.37，貝塔值為 0.49。該公司的債務與股本比率為 0.04，速動比率為 11.01，流動比率為 11.01。</p>
</div><h2>About Viridian Therapeutics</h2>
<div class="lb-trans"><h2>關於 Viridian Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.</p>
<div class="lb-trans"><p>Viridian Therapeutics, Inc.是一家生物技術公司，致力於發現和開發嚴重和罕見疾病的治療方案。該公司的產品管線包括 VRDN-001，一種針對類胰島素生長因子-1 受體的單克隆抗體，目前正在進行治療甲狀腺眼病（TED）的三期臨牀試驗；以及 VRDN-003，一種下一代 IGF-1R 人源化單克隆抗體，針對 IGF-1R 並結合半衰期延長技術用於治療 TED。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Viridian Therapeutics</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Dutch Bros Beats Earnings for 11th Consecutive Quarter</li>
<li>Investing In Automotive Stocks</li>
<li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>AMD’s Price Pullback Equals Opportunity: The Big Gains Are Coming</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Viridian Therapeutics</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>Dutch Bros 連續第 11 個季度超預期盈利</li>
<li>投資汽車股票</li>
<li>從分紅到增長：為什麼這三隻股票在 2025 年脱穎而出</li>
<li>投資者如何找到最佳的便宜分紅股票</li>
<li>AMD 的價格回調意味着機會：大幅收益即將到來</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Viridian Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Viridian Therapeutics 嗎？</h2>
</div><p>Before you consider Viridian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Viridian Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Viridian Therapeutics 並不在名單上。</p>
</div><p>While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Viridian Therapeutics 目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Viridian Therapeutics（NASDAQ:VRDN）因盈利超預期而創下 12 個月新高